A new science-business paradigm in anticancer drug development
A new science-business paradigm in anticancer drug development
复制标题
DOI：
10.1016/s0167-7799(03)00004-0
复制
发表时间：
2003-03-01
影响因子：
17.3
通讯作者：
Blagosklonny, MV
中科院分区：
文献类型：
--
作者：
Blagosklonny, MV
对癌症分子机制的研究表明，除了少数例外，这种疾病缺乏特定的药物靶点。因此，新的抗癌药物不仅需要多年的时间和大量的资金来开发，而且可能不会超过现有的药物。然而，被认为是癌症的不利标志，例如耐药性，可以用于选择性抗癌治疗和保护正常细胞。基于这种模式，药物发现可以通过现有药物甚至“失败”药物的新用途来补充。药理学行业可以开发低成本，有效的治疗方式，通过“再利用”已经上市的晚期产品在癌症选择性治疗试剂盒。
Studies into the molecular mechanisms of cancer have revealed that, with a few exceptions, the disease lacks a specific drug target. Therefore, new anticancer drugs not only take many years and much money to develop but also might not outperform existing drugs. However, what are assumed to be unfavorable hallmarks of cancer, for example drug resistance, can be exploited for selective anticancer therapy and for protection of normal cells. Based on this paradigm, the drug discovery can be complemented by novel use of existing agents and even 'failed' drugs. The pharmacological industry could develop low cost, effective therapeutic modalities, by 're-using' already marketed and late-stage products in cancer-selective therapeutic kits.